 |
Quick Links |
| Information by Disease |
|
|
|
| Cancer News |
|
|
|
| Conference Coverage |
|
|
|
| AZN | $44.82 | -0.37 (-0.82%)
| | NVS | $53.13 | -0.16 (-0.3%)
| | SNY | $37.67 | -0.01 (-0.03%)
| | GSK | $41.53 | 0.06 (0.14%)
|
|
|
Bladder Cancer
| 572016 |
ErbB-2 and EGFR dual kinase inhibitor |
GlaxoSmithKline |
III |
| Advexin (adenoviral p53) |
Gene therapy |
Introgen Therapeutics, NCI |
I |
| Alimta (pemetrexed sodium) |
Multi-targeted antifolate |
Eli Lilly |
II |
| Bexidem |
Macrophage |
IDM |
II/III |
| Celebrex (celecoxib) |
COX inhibitor |
Pfizer |
III |
| CG8840 |
Oncolytic virus |
Cell Genesys |
Pre-clinical |
| Eflornithine (difluoromethylornithine) |
Ornithine decarboxylase inhibitor |
Ilex Oncology Genzyme |
III |
| Eoquin (apezequone) |
Bioreductive prodrug |
Spectrum Pharmaceuticals |
I |
| Fenretinide |
Vitamin A analogue |
NCI |
III |
| Gallium maltolate |
Gallium (semi-metalic) |
Titan Pharmaceuticals |
I/II |
| Hexvix |
Photosensitizing agent |
PhotoCure ASA |
III |
| Levulan PD |
Photodynamic therapy |
DUSA Pharmaceuticals |
II |
| MCC (urocidin) |
Mycobacterial cell wall-DNA complex |
Bioniche Life Sciences |
III |
| Suramin |
Anti-angiogenic |
NCI |
I/II |
| Tempostatin (halafuginone hydrobromide) |
Extracellular matrix protein inhibitor |
Collgard Pharmaceuticals |
II |
| TOCOSOL Paclitaxel (S-8184) |
Taxane |
Sonus Pharmaceuticals |
II |
|
For more information contact us at clinicaltrials@cancerconsultants.com
 |
 View Drugs in Pipeline By Disease |
 |
|
|
|
 |
|
 |
|
|
Patient Home
Meeting Calendar
